Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Feb 1;128(2):573-576.
doi: 10.1172/JCI99035. Epub 2018 Jan 8.

Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis

Comment

Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis

Eleanor Barnes. J Clin Invest. .

Abstract

Hepatitis B virus (HBV) infection can be managed clinically with nucleos(t)ide therapy, which suppresses viral replication; however, these drugs must often be used long term, as they are unable to fully eliminate the virus. For many patients, discontinuation of treatment results in viral resurgence and hepatic flare, and there is not a reliable way to identify those individuals that can be successfully taken off nucleos(t)ide therapy. In this issue of the JCI, Rivino and colleagues report on their use of a multipronged approach to investigate potential biomarkers indicative of HBV-infected patients who can safely stop nucleos(t)ide therapy. The authors identified a population of HBV-specific, PD1-positive T cells that was present in HBV-infected patients who successfully discontinued treatment without hepatic flare, but not in those that developed flare upon treatment cessation. Together, these results support the concept that PD1+ cells may play an important role in viral control, the further evaluation of this T cell subset in preventing hepatic flare, and the development of assays to better detect this PD1+ T cell population in HBV-infected patients on nucleos(t)ide therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: E. Barnes has patents pending for HCV and HBV vaccines and has recently partnered with Vaccitech (a spinout company from the University of Oxford) to develop immunotherapeutic HBV vaccines.

Figures

Figure 1
Figure 1. A schematic representation of PD1 expression and T cell differentiation in viral hepatitis.
PD1 expression and selected discriminatory markers of T cell differentiation and the generation of T cell memory are shown during clinical stages of infection. These include acute and resolved viral infection (blue lines), chronic infection (red lines), and chronic infection with viral suppression with antiviral therapy (green lines). Partially exhausted T cells with memory potential have been shown to play a role in viral suppression during chronic disease in mouse models and can be expanded after therapy following in vivo or ex vivo antigen rechallenge. Tem, effector memory cells; Tcm, central memory cells; Tpex(M), partially exhausted T cells with memory potential.

Comment on

References

    1. Stanaway JD, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–1088. doi: 10.1016/S0140-6736(16)30579-7. - DOI - PMC - PubMed
    1. World Health Organization. Global Hepatitis Report 2017. WHO Website. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ Accessed December 12, 2017.
    1. Papatheodoridis G, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63(5):1481–1492. doi: 10.1002/hep.28438. - DOI - PubMed
    1. Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res. 2017;47(10):1000–1007. doi: 10.1111/hepr.12836. - DOI - PubMed
    1. Jeng WJ, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58(6):1888–1896. doi: 10.1002/hep.26549. - DOI - PubMed

Publication types